Altered states of leadership: mindfulness meditation, psychedelic use, and leadership development.
leaders
leadership
meditation
mindfulness
psilocybin
psychedelics
Journal
Frontiers in psychology
ISSN: 1664-1078
Titre abrégé: Front Psychol
Pays: Switzerland
ID NLM: 101550902
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
01
2023
accepted:
15
06
2023
medline:
21
7
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
epublish
Résumé
Previous research suggests that mindfulness meditation and psychedelic substances show promise as mental health interventions, but relatively little remains known about their potential impact on leadership outcomes. This study aimed to investigate if and how mindfulness meditation and psychedelic use may impact leadership among respondents with a management position as their primary role at work. Using samples representative of the US and UK adult populations with regard to sex, age, and ethnicity, this study used quantitative and qualitative methods to examine if and how mindfulness meditation and psychedelic use may impact leadership. Among respondents with a management position as their primary role at work ( Although causality cannot be inferred due to the research design, the findings in this study suggest potential complementary effects of mindfulness meditation and psychedelic use on leadership, which could inspire new approaches in leadership development.
Sections du résumé
Background
UNASSIGNED
Previous research suggests that mindfulness meditation and psychedelic substances show promise as mental health interventions, but relatively little remains known about their potential impact on leadership outcomes.
Aims
UNASSIGNED
This study aimed to investigate if and how mindfulness meditation and psychedelic use may impact leadership among respondents with a management position as their primary role at work.
Methods
UNASSIGNED
Using samples representative of the US and UK adult populations with regard to sex, age, and ethnicity, this study used quantitative and qualitative methods to examine if and how mindfulness meditation and psychedelic use may impact leadership.
Results
UNASSIGNED
Among respondents with a management position as their primary role at work (
Conclusion
UNASSIGNED
Although causality cannot be inferred due to the research design, the findings in this study suggest potential complementary effects of mindfulness meditation and psychedelic use on leadership, which could inspire new approaches in leadership development.
Identifiants
pubmed: 37476092
doi: 10.3389/fpsyg.2023.1151626
pmc: PMC10354271
doi:
Banques de données
figshare
['10.6084/m9.figshare.23541459.v1']
Types de publication
Journal Article
Langues
eng
Pagination
1151626Subventions
Organisme : NCCIH NIH HHS
ID : K23 AT010879
Pays : United States
Informations de copyright
Copyright © 2023 Simonsson, Stenfors, Goldberg, Hendricks and Osika.
Déclaration de conflit d'intérêts
PH was on the scientific advisory board of Bright Minds Biosciences Ltd., Eleusis Benefit Corporation, and Reset Pharmaceuticals Inc. OS was a co-founder of Eudelics AB. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Psychopharmacol. 2008 Aug;22(6):621-32
pubmed: 18593735
J Psychopharmacol. 2021 Apr;35(4):437-446
pubmed: 33427007
Nordisk Alkohol Nark. 2018 Feb;35(1):39-51
pubmed: 32934512
Behav Res Methods. 2022 Aug;54(4):1643-1662
pubmed: 34590289
Int J Neuropsychopharmacol. 2019 Jul 1;22(7):426-434
pubmed: 31152167
Clin Psychol Sci. 2021 May 18;9(6):1185-1204
pubmed: 35174010
Addiction. 2022 Dec;117(12):3099-3109
pubmed: 35978453
Front Psychiatry. 2020 Mar 31;11:224
pubmed: 32296353
J Appl Psychol. 2003 Oct;88(5):879-903
pubmed: 14516251
Psychopharmacology (Berl). 2021 Feb;238(2):341-354
pubmed: 33427944
J Psychopharmacol. 2022 Mar;36(3):258-272
pubmed: 35107059
ACS Pharmacol Transl Sci. 2021 Mar 16;4(2):416-423
pubmed: 33860171
J Psychopharmacol. 2022 Mar;36(3):348-359
pubmed: 35105186
Proc Natl Acad Sci U S A. 2020 Feb 4;117(5):2338-2346
pubmed: 31964815
Front Pharmacol. 2021 May 19;12:607529
pubmed: 34093170
Int J Drug Policy. 2019 Aug;70:33-39
pubmed: 31071597
J Psychoactive Drugs. 2019 Apr-Jun;51(2):118-122
pubmed: 30925850
Psychopharmacology (Berl). 2006 Aug;187(3):268-83; discussion 284-92
pubmed: 16826400
Addict Behav. 2017 Oct;73:133-136
pubmed: 28511097
J Psychoactive Drugs. 2023 Jan-Mar;55(1):11-18
pubmed: 35000559
Psychopharmacology (Berl). 2018 Dec;235(12):3401-3413
pubmed: 30357434
Front Psychol. 2018 Sep 04;9:1475
pubmed: 30245648